MaxCyte, Inc. (NASDAQ:MXCT – Get Free Report) Director Stanley C. Erck sold 21,607 shares of MaxCyte stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $3.71, for a total value of $80,161.97. Following the completion of the sale, the director now directly owns 269,118 shares in the company, valued at approximately $998,427.78. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
MaxCyte Stock Up 1.1 %
MaxCyte stock traded up $0.04 during trading hours on Wednesday, hitting $3.74. The stock had a trading volume of 410,809 shares, compared to its average volume of 532,271. The business’s 50 day simple moving average is $4.17 and its 200-day simple moving average is $4.26. The stock has a market cap of $392.04 million, a price-to-earnings ratio of -10.57 and a beta of 1.40. MaxCyte, Inc. has a one year low of $2.45 and a one year high of $5.55.
MaxCyte (NASDAQ:MXCT – Get Free Report) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.05. The company had revenue of $10.43 million for the quarter, compared to analyst estimates of $8.20 million. MaxCyte had a negative net margin of 77.97% and a negative return on equity of 15.52%. During the same quarter in the previous year, the firm posted ($0.10) earnings per share. Research analysts anticipate that MaxCyte, Inc. will post -0.44 EPS for the current fiscal year.
Institutional Investors Weigh In On MaxCyte
MaxCyte Company Profile
MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
Read More
- Five stocks we like better than MaxCyte
- Most active stocks: Dollar volume vs share volume
- S&P 500 Hitting Resistance: These 3 Stocks Offer the Best Upside
- Buy P&G Now, Before It Sets A New All-Time High
- Nike’s Post-Earnings Drop Presents a Buying Opportunity
- CD Calculator: Certificate of Deposit Calculator
- Microsoft’s Targeted Upside Might Be Too Good to Ignore
Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.